\babel@toc {english}{}\relax 
\contentsline {part}{I\hspace {1em}Notes}{9}{part.1}%
\contentsline {chapter}{\numberline {1}Introduction}{10}{chapter.1}%
\contentsline {section}{\numberline {1.1}Genetics and genomics}{10}{section.1.1}%
\contentsline {subsection}{\numberline {1.1.1}Genetics}{10}{subsection.1.1.1}%
\contentsline {subsection}{\numberline {1.1.2}Genomics}{10}{subsection.1.1.2}%
\contentsline {subsection}{\numberline {1.1.3}Differences between genetics and genomics}{10}{subsection.1.1.3}%
\contentsline {subsection}{\numberline {1.1.4}The role of computational biology}{11}{subsection.1.1.4}%
\contentsline {section}{\numberline {1.2}Basis of human genomics}{11}{section.1.2}%
\contentsline {subsection}{\numberline {1.2.1}Single nucleotide polymorphisms}{11}{subsection.1.2.1}%
\contentsline {subsection}{\numberline {1.2.2}Copy number variants}{11}{subsection.1.2.2}%
\contentsline {subsection}{\numberline {1.2.3}Inherited variants}{11}{subsection.1.2.3}%
\contentsline {subsubsection}{\numberline {1.2.3.1}Penetrance}{12}{subsubsection.1.2.3.1}%
\contentsline {subsubsection}{\numberline {1.2.3.2}Allele frequency}{12}{subsubsection.1.2.3.2}%
\contentsline {subsubsection}{\numberline {1.2.3.3}Differences in Genetic Make-Up, an example}{12}{subsubsection.1.2.3.3}%
\contentsline {subsection}{\numberline {1.2.4}Somatic Variants}{13}{subsection.1.2.4}%
\contentsline {subsubsection}{\numberline {1.2.4.1}Classification}{13}{subsubsection.1.2.4.1}%
\contentsline {subsubsection}{\numberline {1.2.4.2}Types of acquired DNA aberrations}{13}{subsubsection.1.2.4.2}%
\contentsline {paragraph}{\numberline {1.2.4.2.1}Translocation}{13}{paragraph.1.2.4.2.1}%
\contentsline {paragraph}{\numberline {1.2.4.2.2}Inversion}{13}{paragraph.1.2.4.2.2}%
\contentsline {paragraph}{\numberline {1.2.4.2.3}Copy number changes}{14}{paragraph.1.2.4.2.3}%
\contentsline {paragraph}{\numberline {1.2.4.2.4}Chromoplexy}{14}{paragraph.1.2.4.2.4}%
\contentsline {section}{\numberline {1.3}Experimental techniques to detect variants/aberrations}{14}{section.1.3}%
\contentsline {subsection}{\numberline {1.3.1}Karyotyping}{14}{subsection.1.3.1}%
\contentsline {subsection}{\numberline {1.3.2}Sequence capture for cancer genomics}{14}{subsection.1.3.2}%
\contentsline {subsubsection}{\numberline {1.3.2.1}Reference}{14}{subsubsection.1.3.2.1}%
\contentsline {subsubsection}{\numberline {1.3.2.2}Deepness}{15}{subsubsection.1.3.2.2}%
\contentsline {subsubsection}{\numberline {1.3.2.3}Single End (SE) and Paired End (PE) reads}{15}{subsubsection.1.3.2.3}%
\contentsline {paragraph}{\numberline {1.3.2.3.1}Single end sequencing}{15}{paragraph.1.3.2.3.1}%
\contentsline {paragraph}{\numberline {1.3.2.3.2}Paired end sequencing}{15}{paragraph.1.3.2.3.2}%
\contentsline {paragraph}{\numberline {1.3.2.3.3}Ability of paired end sequencing to detect genomic aberrations}{15}{paragraph.1.3.2.3.3}%
\contentsline {chapter}{\numberline {2}Coverage}{16}{chapter.2}%
\contentsline {section}{\numberline {2.1}Computing coverage}{16}{section.2.1}%
\contentsline {subsection}{\numberline {2.1.1}Local coverage}{16}{subsection.2.1.1}%
\contentsline {subsection}{\numberline {2.1.2}Allelic fraction}{16}{subsection.2.1.2}%
\contentsline {subsection}{\numberline {2.1.3}NGS global coverage}{16}{subsection.2.1.3}%
\contentsline {section}{\numberline {2.2}Mapping in NGS}{16}{section.2.2}%
\contentsline {subsection}{\numberline {2.2.1}Sequence coverage}{17}{subsection.2.2.1}%
\contentsline {subsection}{\numberline {2.2.2}Physical coverage}{17}{subsection.2.2.2}%
\contentsline {section}{\numberline {2.3}Tuning coverage}{17}{section.2.3}%
\contentsline {subsection}{\numberline {2.3.1}SNP detection}{17}{subsection.2.3.1}%
\contentsline {subsection}{\numberline {2.3.2}Subclonal events}{17}{subsection.2.3.2}%
\contentsline {subsection}{\numberline {2.3.3}Amplicon-based approaches}{18}{subsection.2.3.3}%
\contentsline {subsubsection}{\numberline {2.3.3.1}Heterozygous deletion of PTEN}{18}{subsubsection.2.3.3.1}%
\contentsline {subsubsection}{\numberline {2.3.3.2}Homozygous deletion of PTEN}{18}{subsubsection.2.3.3.2}%
\contentsline {subsubsection}{\numberline {2.3.3.3}Amplification of AR}{18}{subsubsection.2.3.3.3}%
\contentsline {subsection}{\numberline {2.3.4}NGS-based approaches}{19}{subsection.2.3.4}%
\contentsline {subsubsection}{\numberline {2.3.4.1}Advantages over amplicon-based approaches}{19}{subsubsection.2.3.4.1}%
\contentsline {subsubsection}{\numberline {2.3.4.2}Problems of NGS-based approaches}{19}{subsubsection.2.3.4.2}%
\contentsline {section}{\numberline {2.4}Databases for NGS analysis}{19}{section.2.4}%
\contentsline {subsection}{\numberline {2.4.1}Genome reference consortium}{19}{subsection.2.4.1}%
\contentsline {subsection}{\numberline {2.4.2}USCS genome browser}{19}{subsection.2.4.2}%
\contentsline {chapter}{\numberline {3}Genetic Fingerprinting}{20}{chapter.3}%
\contentsline {section}{\numberline {3.1}Introduction}{20}{section.3.1}%
\contentsline {subsection}{\numberline {3.1.1}Fields of interest}{20}{subsection.3.1.1}%
\contentsline {subsection}{\numberline {3.1.2}Variants used for genetic testing}{20}{subsection.3.1.2}%
\contentsline {subsubsection}{\numberline {3.1.2.1}CNVs}{20}{subsubsection.3.1.2.1}%
\contentsline {subsubsection}{\numberline {3.1.2.2}SNPs}{21}{subsubsection.3.1.2.2}%
\contentsline {section}{\numberline {3.2}SNPs features}{21}{section.3.2}%
\contentsline {subsection}{\numberline {3.2.1}Hardy-Weinberg equilibrium}{21}{subsection.3.2.1}%
\contentsline {subsection}{\numberline {3.2.2}Minor allele frequency}{21}{subsection.3.2.2}%
\contentsline {subsubsection}{\numberline {3.2.2.1}Optimal MAF values for genetic fingerprinting}{21}{subsubsection.3.2.2.1}%
\contentsline {subsection}{\numberline {3.2.3}Haplotype blocks}{22}{subsection.3.2.3}%
\contentsline {subsubsection}{\numberline {3.2.3.1}Linkage disequilibrium}{22}{subsubsection.3.2.3.1}%
\contentsline {subsubsection}{\numberline {3.2.3.2}Tag SNPs}{22}{subsubsection.3.2.3.2}%
\contentsline {subsection}{\numberline {3.2.4}Other SNP features}{23}{subsection.3.2.4}%
\contentsline {subsection}{\numberline {3.2.5}Number of SNPs to select when performing a genetic test}{23}{subsection.3.2.5}%
\contentsline {subsubsection}{\numberline {3.2.5.1}Experimental mismatches - Genotype call error rate}{23}{subsubsection.3.2.5.1}%
\contentsline {paragraph}{\numberline {3.2.5.1.1}An example on the effect of experimental mismatches}{24}{figure.caption.12}%
\contentsline {subsubsection}{\numberline {3.2.5.2}Biological mismatches}{24}{subsubsection.3.2.5.2}%
\contentsline {paragraph}{\numberline {3.2.5.2.1}Loss of Heterozygosity (LOH)}{24}{paragraph.3.2.5.2.1}%
\contentsline {paragraph}{\numberline {3.2.5.2.2}Gain Of Heterozygosity (GOH)}{24}{paragraph.3.2.5.2.2}%
\contentsline {paragraph}{\numberline {3.2.5.2.3}Double Mutation (DM)}{24}{paragraph.3.2.5.2.3}%
\contentsline {paragraph}{\numberline {3.2.5.2.4}Modelling biological mismatches}{24}{paragraph.3.2.5.2.4}%
\contentsline {subsection}{\numberline {3.2.6}Project regarding SNPs}{25}{subsection.3.2.6}%
\contentsline {subsubsection}{\numberline {3.2.6.1}dbSNPs}{25}{subsubsection.3.2.6.1}%
\contentsline {subsubsection}{\numberline {3.2.6.2}HapMap3}{25}{subsubsection.3.2.6.2}%
\contentsline {section}{\numberline {3.3}Genetic distance}{25}{section.3.3}%
\contentsline {subsection}{\numberline {3.3.1}Measuring distance}{25}{subsection.3.3.1}%
\contentsline {subsubsection}{\numberline {3.3.1.1}Expected distance}{27}{subsubsection.3.3.1.1}%
\contentsline {subsubsection}{\numberline {3.3.1.2}Identifying a sample origin from RAP samples}{28}{subsubsection.3.3.1.2}%
\contentsline {subsection}{\numberline {3.3.2}Distance changes with different numbers of SNPs}{29}{subsection.3.3.2}%
\contentsline {section}{\numberline {3.4}Building a SNP-based genetic test}{29}{section.3.4}%
\contentsline {subsection}{\numberline {3.4.1}Pipeline}{29}{subsection.3.4.1}%
\contentsline {subsection}{\numberline {3.4.2}Implementation of a probabilistic test to identify samples}{30}{subsection.3.4.2}%
\contentsline {subsubsection}{\numberline {3.4.2.1}Classification}{30}{subsubsection.3.4.2.1}%
\contentsline {subsection}{\numberline {3.4.3}Some examples of genetic tests}{31}{subsection.3.4.3}%
\contentsline {subsubsection}{\numberline {3.4.3.1}Investigating cell line passages}{31}{subsubsection.3.4.3.1}%
\contentsline {subsubsection}{\numberline {3.4.3.2}Investigating individual relatedness}{31}{subsubsection.3.4.3.2}%
\contentsline {subsection}{\numberline {3.4.4}Genetic structure of the human population}{32}{subsection.3.4.4}%
\contentsline {subsubsection}{\numberline {3.4.4.1}Genes mirror geography in Europe}{33}{subsubsection.3.4.4.1}%
\contentsline {chapter}{\numberline {4}IGV (Integrative Genomics Viewer)}{35}{chapter.4}%
\contentsline {section}{\numberline {4.1}IGV characteristics}{35}{section.4.1}%
\contentsline {subsection}{\numberline {4.1.1}Introduction}{35}{subsection.4.1.1}%
\contentsline {subsection}{\numberline {4.1.2}Main uses of IGV}{35}{subsection.4.1.2}%
\contentsline {subsubsection}{\numberline {4.1.2.1}RNA sequence analysis}{36}{subsubsection.4.1.2.1}%
\contentsline {subsubsection}{\numberline {4.1.2.2}Variant discovery}{37}{subsubsection.4.1.2.2}%
\contentsline {subsection}{\numberline {4.1.3}Operations}{37}{subsection.4.1.3}%
\contentsline {subsection}{\numberline {4.1.4}Tiles}{38}{subsection.4.1.4}%
\contentsline {subsubsection}{\numberline {4.1.4.1}Pixel resolution error}{38}{subsubsection.4.1.4.1}%
\contentsline {subsubsection}{\numberline {4.1.4.2}Data displayed at different resolutions}{39}{subsubsection.4.1.4.2}%
\contentsline {subsection}{\numberline {4.1.5}IGVTools}{39}{subsection.4.1.5}%
\contentsline {subsection}{\numberline {4.1.6}Session files}{39}{subsection.4.1.6}%
\contentsline {section}{\numberline {4.2}Interpreting pair orientations}{40}{section.4.2}%
\contentsline {subsection}{\numberline {4.2.1}Element to consider when interpreting pair orientations}{40}{subsection.4.2.1}%
\contentsline {subsection}{\numberline {4.2.2}Inversion}{40}{subsection.4.2.2}%
\contentsline {subsection}{\numberline {4.2.3}Tandem duplication}{41}{subsection.4.2.3}%
\contentsline {subsection}{\numberline {4.2.4}Inverted duplication}{41}{subsection.4.2.4}%
\contentsline {subsection}{\numberline {4.2.5}Deletion}{42}{subsection.4.2.5}%
\contentsline {section}{\numberline {4.3}Uncovering genetic aberrations - some examples}{42}{section.4.3}%
\contentsline {subsection}{\numberline {4.3.1}First example}{42}{subsection.4.3.1}%
\contentsline {subsection}{\numberline {4.3.2}Second example}{42}{subsection.4.3.2}%
\contentsline {subsection}{\numberline {4.3.3}Third example}{43}{subsection.4.3.3}%
\contentsline {chapter}{\numberline {5}Tumor Evolution Studies via NGS data}{45}{chapter.5}%
\contentsline {section}{\numberline {5.1}Tumour evolution}{45}{section.5.1}%
\contentsline {subsection}{\numberline {5.1.1}Introduction}{45}{subsection.5.1.1}%
\contentsline {subsubsection}{\numberline {5.1.1.1}Typical traits of cancer}{45}{subsubsection.5.1.1.1}%
\contentsline {subsubsection}{\numberline {5.1.1.2}Tumour boards}{45}{subsubsection.5.1.1.2}%
\contentsline {subsection}{\numberline {5.1.2}Heterogeneity}{46}{subsection.5.1.2}%
\contentsline {subsubsection}{\numberline {5.1.2.1}Temporal heterogeneity}{46}{subsubsection.5.1.2.1}%
\contentsline {subsubsection}{\numberline {5.1.2.2}Spatial heterogeneity}{46}{subsubsection.5.1.2.2}%
\contentsline {subsection}{\numberline {5.1.3}Type of evolutions}{46}{subsection.5.1.3}%
\contentsline {subsubsection}{\numberline {5.1.3.1}Linear evolution}{47}{subsubsection.5.1.3.1}%
\contentsline {subsubsection}{\numberline {5.1.3.2}Branched evolution}{47}{subsubsection.5.1.3.2}%
\contentsline {subsection}{\numberline {5.1.4}Treatment resistance}{47}{subsection.5.1.4}%
\contentsline {subsubsection}{\numberline {5.1.4.1}Primary resistance}{48}{subsubsection.5.1.4.1}%
\contentsline {subsubsection}{\numberline {5.1.4.2}Acquired resistance}{48}{subsubsection.5.1.4.2}%
\contentsline {section}{\numberline {5.2}Using NGS data to uncover tumour evolution}{48}{section.5.2}%
\contentsline {subsection}{\numberline {5.2.1}Introduction}{48}{subsection.5.2.1}%
\contentsline {subsection}{\numberline {5.2.2}Admixture}{49}{subsection.5.2.2}%
\contentsline {subsection}{\numberline {5.2.3}Informative SNPs}{49}{subsection.5.2.3}%
\contentsline {subsection}{\numberline {5.2.4}Beta value}{50}{subsection.5.2.4}%
\contentsline {subsubsection}{\numberline {5.2.4.1}Computing beta}{51}{subsubsection.5.2.4.1}%
\contentsline {subsubsection}{\numberline {5.2.4.2}Effect of coverage on beta}{52}{subsubsection.5.2.4.2}%
\contentsline {subsection}{\numberline {5.2.5}Estimates of global and local admixture}{52}{subsection.5.2.5}%
\contentsline {subsubsection}{\numberline {5.2.5.1}Estimates of DNA admixture}{53}{subsubsection.5.2.5.1}%
\contentsline {subsection}{\numberline {5.2.6}PR-2741 - an example}{54}{subsection.5.2.6}%
\contentsline {chapter}{\numberline {6}Tumor evolution studies: copy number based methods}{56}{chapter.6}%
\contentsline {section}{\numberline {6.1}Analysis of clonality}{56}{section.6.1}%
\contentsline {subsection}{\numberline {6.1.1}Informative SNPs}{56}{subsection.6.1.1}%
\contentsline {subsection}{\numberline {6.1.2}Log2 ratio}{56}{subsection.6.1.2}%
\contentsline {subsection}{\numberline {6.1.3}Beta value}{57}{subsection.6.1.3}%
\contentsline {subsection}{\numberline {6.1.4}Cluster analysis in the beta-log2 ratio space}{57}{subsection.6.1.4}%
\contentsline {section}{\numberline {6.2}Evolution maps}{58}{section.6.2}%
\contentsline {subsection}{\numberline {6.2.1}Introduction}{58}{subsection.6.2.1}%
\contentsline {subsection}{\numberline {6.2.2}Building an evolution map}{58}{subsection.6.2.2}%
\contentsline {subsection}{\numberline {6.2.3}A toy example}{58}{subsection.6.2.3}%
\contentsline {subsection}{\numberline {6.2.4}A real world data example}{60}{subsection.6.2.4}%
\contentsline {subsubsection}{\numberline {6.2.4.1}Limitations}{60}{subsubsection.6.2.4.1}%
\contentsline {subsection}{\numberline {6.2.5}Pathway-based evolutionary maps}{60}{subsection.6.2.5}%
\contentsline {subsubsection}{\numberline {6.2.5.1}Timing}{61}{subsubsection.6.2.5.1}%
\contentsline {subsubsection}{\numberline {6.2.5.2}Treatment}{61}{subsubsection.6.2.5.2}%
\contentsline {section}{\numberline {6.3}Ploidy and purity corrections}{61}{section.6.3}%
\contentsline {subsection}{\numberline {6.3.1}Introduction}{61}{subsection.6.3.1}%
\contentsline {subsection}{\numberline {6.3.2}A melanoma example}{62}{subsection.6.3.2}%
\contentsline {subsubsection}{\numberline {6.3.2.1}Ploidy correction}{62}{subsubsection.6.3.2.1}%
\contentsline {subsubsection}{\numberline {6.3.2.2}Purity correction}{63}{subsubsection.6.3.2.2}%
\contentsline {subsection}{\numberline {6.3.3}A melanoma example considering more samples}{63}{subsection.6.3.3}%
\contentsline {subsection}{\numberline {6.3.4}An example with TGCA data}{64}{subsection.6.3.4}%
\contentsline {subsubsection}{\numberline {6.3.4.1}Ploidy correction}{64}{subsubsection.6.3.4.1}%
\contentsline {section}{\numberline {6.4}Allele-specific analysis}{65}{section.6.4}%
\contentsline {subsection}{\numberline {6.4.1}Introduction}{65}{subsection.6.4.1}%
\contentsline {subsection}{\numberline {6.4.2}An example}{66}{subsection.6.4.2}%
\contentsline {subsubsection}{\numberline {6.4.2.1}Changes of copy number for specific alleles}{67}{subsubsection.6.4.2.1}%
\contentsline {subsubsection}{\numberline {6.4.2.2}Copy number neutral events}{67}{subsubsection.6.4.2.2}%
\contentsline {subsection}{\numberline {6.4.3}A case study}{68}{subsection.6.4.3}%
\contentsline {subsubsection}{\numberline {6.4.3.1}Primary site}{69}{subsubsection.6.4.3.1}%
\contentsline {subsubsection}{\numberline {6.4.3.2}Metastasis}{69}{subsubsection.6.4.3.2}%
\contentsline {section}{\numberline {6.5}Longitudinal plasma profiling}{70}{section.6.5}%
\contentsline {subsection}{\numberline {6.5.1}An example}{70}{subsection.6.5.1}%
\contentsline {subsection}{\numberline {6.5.2}Tracking evolution}{71}{subsection.6.5.2}%
\contentsline {chapter}{\numberline {7}Tumor evolution studies: SNVs-based methods}{72}{chapter.7}%
\contentsline {section}{\numberline {7.1}Introduction}{72}{section.7.1}%
\contentsline {subsection}{\numberline {7.1.1}Copy-number neutral tumours}{72}{subsection.7.1.1}%
\contentsline {subsection}{\numberline {7.1.2}Different methods for tumour assessment}{73}{subsection.7.1.2}%
\contentsline {subsection}{\numberline {7.1.3}Rationale of SNV based methods}{73}{subsection.7.1.3}%
\contentsline {subsection}{\numberline {7.1.4}Advantages and limitations of SNVs based methods}{73}{subsection.7.1.4}%
\contentsline {subsection}{\numberline {7.1.5}Reference mapping bias}{74}{subsection.7.1.5}%
\contentsline {section}{\numberline {7.2}TPES - tumour purity estimation from SNVs}{74}{section.7.2}%
\contentsline {subsection}{\numberline {7.2.1}Introduction}{74}{subsection.7.2.1}%
\contentsline {subsection}{\numberline {7.2.2}SNV identification}{74}{subsection.7.2.2}%
\contentsline {subsubsection}{\numberline {7.2.2.1}Selection of copy-number neutral segments}{75}{subsubsection.7.2.2.1}%
\contentsline {subsubsection}{\numberline {7.2.2.2}Allelic fraction}{75}{subsubsection.7.2.2.2}%
\contentsline {subsubsection}{\numberline {7.2.2.3}Identification of putative clonal SNVs}{75}{subsubsection.7.2.2.3}%
\contentsline {subsection}{\numberline {7.2.3}Purity estimation}{75}{subsection.7.2.3}%
\contentsline {subsection}{\numberline {7.2.4}Minimal number of SNV for tumour identification}{75}{subsection.7.2.4}%
\contentsline {subsection}{\numberline {7.2.5}Comparison with other tumour callers}{76}{subsection.7.2.5}%
\contentsline {chapter}{\numberline {8}Liquid biopsies in oncology}{77}{chapter.8}%
\contentsline {section}{\numberline {8.1}Introduction}{77}{section.8.1}%
\contentsline {subsection}{\numberline {8.1.1}Tracking tumour progression}{77}{subsection.8.1.1}%
\contentsline {subsection}{\numberline {8.1.2}Differences between tissue and liquid biopsies}{77}{subsection.8.1.2}%
\contentsline {subsubsection}{\numberline {8.1.2.1}Liquid biopsies allow to perform a number of analysis}{78}{subsubsection.8.1.2.1}%
\contentsline {subsubsection}{\numberline {8.1.2.2}Material availability}{78}{subsubsection.8.1.2.2}%
\contentsline {subsubsection}{\numberline {8.1.2.3}Tumour content}{78}{subsubsection.8.1.2.3}%
\contentsline {subsubsection}{\numberline {8.1.2.4}Assessment of tumour ploidy}{78}{subsubsection.8.1.2.4}%
\contentsline {subsection}{\numberline {8.1.3}Application-dependent requirements}{79}{subsection.8.1.3}%
\contentsline {subsubsection}{\numberline {8.1.3.1}Early tumour, MRD and recurrence detection}{79}{subsubsection.8.1.3.1}%
\contentsline {subsubsection}{\numberline {8.1.3.2}Analysis of tumour dynamics, treatment response and analysis of the mechanisms of resistance}{79}{subsubsection.8.1.3.2}%
\contentsline {subsubsection}{\numberline {8.1.3.3}Single biomarker assessment}{79}{subsubsection.8.1.3.3}%
\contentsline {subsection}{\numberline {8.1.4}Whole-genome and targeted sequencing}{79}{subsection.8.1.4}%
\contentsline {subsection}{\numberline {8.1.5}Challenges in tracking tumour evolution with liquid biopsies}{80}{subsection.8.1.5}%
\contentsline {subsubsection}{\numberline {8.1.5.1}An example of similarity between two plasma samples between two different tumours}{80}{subsubsection.8.1.5.1}%
\contentsline {section}{\numberline {8.2}Interpretation of cell free DNA data}{80}{section.8.2}%
\contentsline {subsection}{\numberline {8.2.1}Introduction}{80}{subsection.8.2.1}%
\contentsline {subsection}{\numberline {8.2.2}Normalization}{80}{subsection.8.2.2}%
\contentsline {subsection}{\numberline {8.2.3}Quantity of input material}{81}{subsection.8.2.3}%
\contentsline {subsection}{\numberline {8.2.4}SNVs detection}{82}{subsection.8.2.4}%
\contentsline {subsubsection}{\numberline {8.2.4.1}Technical problems}{82}{subsubsection.8.2.4.1}%
\contentsline {subsubsection}{\numberline {8.2.4.2}Biological problems}{83}{subsubsection.8.2.4.2}%
\contentsline {subsection}{\numberline {8.2.5}Two case studies}{83}{subsection.8.2.5}%
\contentsline {subsubsection}{\numberline {8.2.5.1}Signal distribution in prostate cancer}{83}{subsubsection.8.2.5.1}%
\contentsline {subsubsection}{\numberline {8.2.5.2}Non-AR driven castration resistance prostate cancer}{83}{subsubsection.8.2.5.2}%
\contentsline {chapter}{\numberline {9}Extracellular vesicles}{85}{chapter.9}%
\contentsline {section}{\numberline {9.1}Introduction}{85}{section.9.1}%
\contentsline {subsection}{\numberline {9.1.1}Definition}{85}{subsection.9.1.1}%
\contentsline {subsection}{\numberline {9.1.2}Compartments of extracellular vesicles}{85}{subsection.9.1.2}%
\contentsline {subsubsection}{\numberline {9.1.2.1}Outside layer}{85}{subsubsection.9.1.2.1}%
\contentsline {subsubsection}{\numberline {9.1.2.2}Content}{85}{subsubsection.9.1.2.2}%
\contentsline {subsubsection}{\numberline {9.1.2.3}Membrane proteins}{86}{subsubsection.9.1.2.3}%
\contentsline {subsection}{\numberline {9.1.3}Characterization of extracellular vesicles}{86}{subsection.9.1.3}%
\contentsline {subsubsection}{\numberline {9.1.3.1}Size}{86}{subsubsection.9.1.3.1}%
\contentsline {subsubsection}{\numberline {9.1.3.2}Origin}{86}{subsubsection.9.1.3.2}%
\contentsline {paragraph}{\numberline {9.1.3.2.1}Process of origin of exosomes}{86}{paragraph.9.1.3.2.1}%
\contentsline {subsubsection}{\numberline {9.1.3.3}Content}{87}{subsubsection.9.1.3.3}%
\contentsline {paragraph}{\numberline {9.1.3.3.1}Exosomes and microvesicles}{87}{paragraph.9.1.3.3.1}%
\contentsline {paragraph}{\numberline {9.1.3.3.2}Apoptotic bodies}{87}{paragraph.9.1.3.3.2}%
\contentsline {paragraph}{\numberline {9.1.3.3.3}Exosomes}{87}{paragraph.9.1.3.3.3}%
\contentsline {subsection}{\numberline {9.1.4}Functions of extracellular vesicles}{88}{subsection.9.1.4}%
\contentsline {subsubsection}{\numberline {9.1.4.1}Functions of extracellular vesicles in cancer}{88}{subsubsection.9.1.4.1}%
\contentsline {section}{\numberline {9.2}Tumour studies through extracellular vesicles analysis}{88}{section.9.2}%
\contentsline {subsection}{\numberline {9.2.1}Introduction}{88}{subsection.9.2.1}%
\contentsline {subsection}{\numberline {9.2.2}Breast cancer - an example}{89}{subsection.9.2.2}%
\contentsline {subsection}{\numberline {9.2.3}Tracking tumour signal in serial samples}{89}{subsection.9.2.3}%
\contentsline {subsection}{\numberline {9.2.4}Extracellular vesicles isolation methods}{89}{subsection.9.2.4}%
\contentsline {subsection}{\numberline {9.2.5}Challenges in studying tumour evolution through extracellular vesicles}{90}{subsection.9.2.5}%
\contentsline {subsection}{\numberline {9.2.6}Deconvolution}{90}{subsection.9.2.6}%
\contentsline {subsubsection}{\numberline {9.2.6.1}Supervised deconvolution}{90}{subsubsection.9.2.6.1}%
\contentsline {subsubsection}{\numberline {9.2.6.2}Unsupervised deconvolution}{91}{subsubsection.9.2.6.2}%
\contentsline {subsection}{\numberline {9.2.7}Conclusion}{91}{subsection.9.2.7}%
\contentsline {chapter}{\numberline {10}Epigenetic profiling of cell-free DNA}{92}{chapter.10}%
\contentsline {section}{\numberline {10.1}Introduction}{92}{section.10.1}%
\contentsline {subsection}{\numberline {10.1.1}Epigenetic}{92}{subsection.10.1.1}%
\contentsline {subsubsection}{\numberline {10.1.1.1}Epigenetic modifications}{92}{subsubsection.10.1.1.1}%
\contentsline {subsubsection}{\numberline {10.1.1.2}Epigenetic plasticity}{92}{subsubsection.10.1.1.2}%
\contentsline {subsubsection}{\numberline {10.1.1.3}Epigenetic deregulation}{92}{subsubsection.10.1.1.3}%
\contentsline {subsection}{\numberline {10.1.2}DNA methylation}{92}{subsection.10.1.2}%
\contentsline {subsubsection}{\numberline {10.1.2.1}CpG islands}{93}{subsubsection.10.1.2.1}%
\contentsline {subsubsection}{\numberline {10.1.2.2}Cancer tissues}{93}{subsubsection.10.1.2.2}%
\contentsline {subsubsection}{\numberline {10.1.2.3}Landscape of regulation}{93}{subsubsection.10.1.2.3}%
\contentsline {subsubsection}{\numberline {10.1.2.4}DNA methylation markers}{94}{subsubsection.10.1.2.4}%
\contentsline {subsection}{\numberline {10.1.3}Measuring DNA methylation}{94}{subsection.10.1.3}%
\contentsline {subsubsection}{\numberline {10.1.3.1}Bisulphite conversion}{94}{subsubsection.10.1.3.1}%
\contentsline {subsubsection}{\numberline {10.1.3.2}Sequencing and alignment}{94}{subsubsection.10.1.3.2}%
\contentsline {subsubsection}{\numberline {10.1.3.3}Computing beta values}{94}{subsubsection.10.1.3.3}%
\contentsline {subsubsection}{\numberline {10.1.3.4}Single read analysis}{95}{subsubsection.10.1.3.4}%
\contentsline {section}{\numberline {10.2}DNA methylation based liquid biopsy}{95}{section.10.2}%
\contentsline {subsection}{\numberline {10.2.1}Introduction}{95}{subsection.10.2.1}%
\contentsline {subsection}{\numberline {10.2.2}Comparison with genomics-based liquid biopsies}{95}{subsection.10.2.2}%
\contentsline {subsection}{\numberline {10.2.3}Workflow}{96}{subsection.10.2.3}%
\contentsline {subsection}{\numberline {10.2.4}CCGA study}{96}{subsection.10.2.4}%
\contentsline {subsubsection}{\numberline {10.2.4.1}Obtaining methylation profiles}{96}{subsubsection.10.2.4.1}%
\contentsline {subsubsection}{\numberline {10.2.4.2}Results}{97}{subsubsection.10.2.4.2}%
\contentsline {subsection}{\numberline {10.2.5}Deconvolution approach}{97}{subsection.10.2.5}%
\contentsline {subsubsection}{\numberline {10.2.5.1}Considering liquid biopsies}{97}{subsubsection.10.2.5.1}%
\contentsline {subsubsection}{\numberline {10.2.5.2}High-quality reference atlases}{97}{subsubsection.10.2.5.2}%
\contentsline {subsection}{\numberline {10.2.6}Targeted panel approaches for tumour content estimation}{97}{subsection.10.2.6}%
\contentsline {part}{II\hspace {1em}Laboratory}{98}{part.2}%
\contentsline {chapter}{\numberline {11}Relevant file's formats}{99}{chapter.11}%
\contentsline {section}{\numberline {11.1}FASTA format}{99}{section.11.1}%
\contentsline {subsection}{\numberline {11.1.1}Components}{99}{subsection.11.1.1}%
\contentsline {subsection}{\numberline {11.1.2}Alphabet}{99}{subsection.11.1.2}%
\contentsline {subsection}{\numberline {11.1.3}DNA sequence quality}{99}{subsection.11.1.3}%
\contentsline {section}{\numberline {11.2}FASTQ format}{100}{section.11.2}%
\contentsline {subsection}{\numberline {11.2.1}Data compression}{100}{subsection.11.2.1}%
\contentsline {section}{\numberline {11.3}SAM and BAM formats}{100}{section.11.3}%
\contentsline {subsection}{\numberline {11.3.1}SAM files}{100}{subsection.11.3.1}%
\contentsline {subsubsection}{\numberline {11.3.1.1}COmposition}{100}{subsubsection.11.3.1.1}%
\contentsline {subsection}{\numberline {11.3.2}BAM files}{100}{subsection.11.3.2}%
\contentsline {subsection}{\numberline {11.3.3}Operation with SAM and BAM files}{100}{subsection.11.3.3}%
\contentsline {subsubsection}{\numberline {11.3.3.1}Converting from SAM to BAM}{101}{subsubsection.11.3.3.1}%
\contentsline {subsubsection}{\numberline {11.3.3.2}Filtering}{101}{subsubsection.11.3.3.2}%
\contentsline {subsubsection}{\numberline {11.3.3.3}Explore statistics}{101}{subsubsection.11.3.3.3}%
\contentsline {subsubsection}{\numberline {11.3.3.4}Mpileup}{101}{subsubsection.11.3.3.4}%
\contentsline {chapter}{\numberline {12}Data pre-processing}{102}{chapter.12}%
\contentsline {section}{\numberline {12.1}Realignment}{102}{section.12.1}%
\contentsline {subsection}{\numberline {12.1.1}Introduction}{102}{subsection.12.1.1}%
\contentsline {subsection}{\numberline {12.1.2}An example}{102}{subsection.12.1.2}%
\contentsline {subsection}{\numberline {12.1.3}Objective of realignment}{102}{subsection.12.1.3}%
\contentsline {subsection}{\numberline {12.1.4}GATK}{102}{subsection.12.1.4}%
\contentsline {subsection}{\numberline {12.1.5}Protocol}{103}{subsection.12.1.5}%
\contentsline {subsection}{\numberline {12.1.6}Realignment results}{103}{subsection.12.1.6}%
\contentsline {section}{\numberline {12.2}Recalibration}{103}{section.12.2}%
\contentsline {subsection}{\numberline {12.2.1}Introduction}{103}{subsection.12.2.1}%
\contentsline {subsubsection}{\numberline {12.2.1.1}Dealing with systematic errors}{103}{subsubsection.12.2.1.1}%
\contentsline {subsection}{\numberline {12.2.2}Computing empirical qualities}{103}{subsection.12.2.2}%
\contentsline {subsubsection}{\numberline {12.2.2.1}Base quality score recalibration}{104}{subsubsection.12.2.2.1}%
\contentsline {subsection}{\numberline {12.2.3}Protocol}{104}{subsection.12.2.3}%
\contentsline {section}{\numberline {12.3}Marking duplicates}{104}{section.12.3}%
\contentsline {subsection}{\numberline {12.3.1}Introduction}{104}{subsection.12.3.1}%
\contentsline {subsection}{\numberline {12.3.2}Identification of duplicates}{104}{subsection.12.3.2}%
\contentsline {subsubsection}{\numberline {12.3.2.1}Consideration on Borrow-Wheeler aligner}{105}{subsubsection.12.3.2.1}%
\contentsline {subsection}{\numberline {12.3.3}Protocol}{105}{subsection.12.3.3}%
\contentsline {chapter}{\numberline {13}Variant calling}{106}{chapter.13}%
\contentsline {section}{\numberline {13.1}Introduction}{106}{section.13.1}%
\contentsline {subsection}{\numberline {13.1.1}Objective of variant calling}{106}{subsection.13.1.1}%
\contentsline {subsection}{\numberline {13.1.2}Bayes' rule for variant calling}{106}{subsection.13.1.2}%
\contentsline {section}{\numberline {13.2}Likelihood estimation for variant calling}{106}{section.13.2}%
\contentsline {subsection}{\numberline {13.2.1}Available tools}{107}{subsection.13.2.1}%
\contentsline {section}{\numberline {13.3}VCF files}{107}{section.13.3}%
\contentsline {subsection}{\numberline {13.3.1}Composition}{107}{subsection.13.3.1}%
\contentsline {subsection}{\numberline {13.3.2}Vcftools}{107}{subsection.13.3.2}%
\contentsline {section}{\numberline {13.4}A variant calling protocol}{108}{section.13.4}%
\contentsline {chapter}{\numberline {14}Variant annotation}{109}{chapter.14}%
\contentsline {section}{\numberline {14.1}Introduction}{109}{section.14.1}%
\contentsline {subsection}{\numberline {14.1.1}Annotation databases}{109}{subsection.14.1.1}%
\contentsline {subsubsection}{\numberline {14.1.1.1}Genomic data repositories}{109}{subsubsection.14.1.1.1}%
\contentsline {subsubsection}{\numberline {14.1.1.2}Variant-disease databases}{109}{subsubsection.14.1.1.2}%
\contentsline {subsubsection}{\numberline {14.1.1.3}Conservation and pathogenicity prediction databases}{109}{subsubsection.14.1.1.3}%
\contentsline {section}{\numberline {14.2}SnpEff}{110}{section.14.2}%
\contentsline {subsection}{\numberline {14.2.1}Introduction}{110}{subsection.14.2.1}%
\contentsline {subsection}{\numberline {14.2.2}Set of transcripts}{110}{subsection.14.2.2}%
\contentsline {subsection}{\numberline {14.2.3}Populating the VCF}{110}{subsection.14.2.3}%
\contentsline {subsection}{\numberline {14.2.4}Common annotations}{110}{subsection.14.2.4}%
\contentsline {subsection}{\numberline {14.2.5}SnpSift}{110}{subsection.14.2.5}%
\contentsline {chapter}{\numberline {15}Ancestry}{111}{chapter.15}%
\contentsline {section}{\numberline {15.1}Introduction}{111}{section.15.1}%
\contentsline {subsection}{\numberline {15.1.1}Population stratification}{111}{subsection.15.1.1}%
\contentsline {subsection}{\numberline {15.1.2}Methods}{111}{subsection.15.1.2}%
\contentsline {subsubsection}{\numberline {15.1.2.1}Principal Component analysis based methods}{111}{subsubsection.15.1.2.1}%
\contentsline {subsubsection}{\numberline {15.1.2.2}Model based methods}{111}{subsubsection.15.1.2.2}%
\contentsline {section}{\numberline {15.2}SMARTPCA}{111}{section.15.2}%
\contentsline {subsection}{\numberline {15.2.1}Introduction}{111}{subsection.15.2.1}%
\contentsline {subsection}{\numberline {15.2.2}PED format}{112}{subsection.15.2.2}%
\contentsline {subsection}{\numberline {15.2.3}Output}{112}{subsection.15.2.3}%
\contentsline {section}{\numberline {15.3}fastSTRUCTURE}{112}{section.15.3}%
\contentsline {subsection}{\numberline {15.3.1}Input}{112}{subsection.15.3.1}%
\contentsline {subsection}{\numberline {15.3.2}Output}{112}{subsection.15.3.2}%
\contentsline {section}{\numberline {15.4}EthSEQ}{112}{section.15.4}%
\contentsline {subsection}{\numberline {15.4.1}Introduction}{112}{subsection.15.4.1}%
\contentsline {subsection}{\numberline {15.4.2}Analysing sequencing data}{113}{subsection.15.4.2}%
\contentsline {subsection}{\numberline {15.4.3}Multi step refinement}{113}{subsection.15.4.3}%
\contentsline {subsection}{\numberline {15.4.4}Dealing with ambiguous points}{113}{subsection.15.4.4}%
\contentsline {chapter}{\numberline {16}Somatic variant calling}{114}{chapter.16}%
\contentsline {section}{\numberline {16.1}Introduction}{114}{section.16.1}%
\contentsline {subsection}{\numberline {16.1.1}Genomic alterations}{114}{subsection.16.1.1}%
\contentsline {subsection}{\numberline {16.1.2}Methods}{114}{subsection.16.1.2}%
\contentsline {subsection}{\numberline {16.1.3}Choosing a caller}{115}{subsection.16.1.3}%
\contentsline {subsection}{\numberline {16.1.4}JointSNVMix and VarScan2}{115}{subsection.16.1.4}%
\contentsline {section}{\numberline {16.2}Varscan 2}{115}{section.16.2}%
\contentsline {subsection}{\numberline {16.2.1}Introduction}{115}{subsection.16.2.1}%
\contentsline {subsection}{\numberline {16.2.2}Calling variants}{115}{subsection.16.2.2}%
\contentsline {subsubsection}{\numberline {16.2.2.1}Tumour matches normal}{115}{subsubsection.16.2.2.1}%
\contentsline {subsubsection}{\numberline {16.2.2.2}Tumour does not match normal}{115}{subsubsection.16.2.2.2}%
\contentsline {subsection}{\numberline {16.2.3}Filtering}{116}{subsection.16.2.3}%
\contentsline {chapter}{\numberline {17}Somatic copy number calling}{117}{chapter.17}%
\contentsline {part}{III\hspace {1em}Papers}{118}{part.3}%
\contentsline {chapter}{\numberline {18}Role of non-coding sequence variants in cancer}{119}{chapter.18}%
\contentsline {section}{\numberline {18.1}Abstract}{119}{section.18.1}%
\contentsline {subsection}{\numberline {18.1.1}Introduction}{119}{subsection.18.1.1}%
\contentsline {section}{\numberline {18.2}Genomic sequence variants}{119}{section.18.2}%
\contentsline {section}{\numberline {18.3}Non-coding element annotation}{120}{section.18.3}%
\contentsline {subsection}{\numberline {18.3.1}Cis regulatory regions}{120}{subsection.18.3.1}%
\contentsline {subsection}{\numberline {18.3.2}Distal regulatory elements}{120}{subsection.18.3.2}%
\contentsline {subsection}{\numberline {18.3.3}RNA-seq}{120}{subsection.18.3.3}%
\contentsline {subsection}{\numberline {18.3.4}Transcribed pseudogenes}{120}{subsection.18.3.4}%
\contentsline {subsection}{\numberline {18.3.5}Evolutionary conservation}{121}{subsection.18.3.5}%
\contentsline {section}{\numberline {18.4}Roles for somatic variants in cancer}{121}{section.18.4}%
\contentsline {subsection}{\numberline {18.4.1}Gain of TF-binding sites}{121}{subsection.18.4.1}%
\contentsline {subsection}{\numberline {18.4.2}Fusion events due to genomic rearrangements}{121}{subsection.18.4.2}%
\contentsline {subsection}{\numberline {18.4.3}ncRNAs and their binding sites}{121}{subsection.18.4.3}%
\contentsline {subsection}{\numberline {18.4.4}Role of pseudogenes in modulating the expression of a parental gene}{122}{subsection.18.4.4}%
\contentsline {section}{\numberline {18.5}Roles for germline variants in cancer}{122}{section.18.5}%
\contentsline {subsection}{\numberline {18.5.1}Promoter mutations}{122}{subsection.18.5.1}%
\contentsline {subsection}{\numberline {18.5.2}SNPs in enhancers}{122}{subsection.18.5.2}%
\contentsline {subsection}{\numberline {18.5.3}Variants in introns}{122}{subsection.18.5.3}%
\contentsline {subsection}{\numberline {18.5.4}SNPs in ncRNA and their binding sites}{122}{subsection.18.5.4}%
\contentsline {subsection}{\numberline {18.5.5}Others}{122}{subsection.18.5.5}%
\contentsline {section}{\numberline {18.6}Interplay between germline and somatic variants}{122}{section.18.6}%
\contentsline {section}{\numberline {18.7}Computational methods for identifying variants}{123}{section.18.7}%
\contentsline {section}{\numberline {18.8}Experimental approaches for functional validation}{123}{section.18.8}%
\contentsline {chapter}{\numberline {19}Advances in understanding cancer genomics through second-generation sequencing}{125}{chapter.19}%
\contentsline {section}{\numberline {19.1}Abstract}{125}{section.19.1}%
\contentsline {subsection}{\numberline {19.1.1}Introduction}{125}{subsection.19.1.1}%
\contentsline {section}{\numberline {19.2}Cancer-specific consideration}{125}{section.19.2}%
\contentsline {subsection}{\numberline {19.2.1}Characteristics of cancer samples for genomic analysis}{126}{subsection.19.2.1}%
\contentsline {subsection}{\numberline {19.2.2}Structural variability of cancer genomes}{126}{subsection.19.2.2}%
\contentsline {section}{\numberline {19.3}Experimental approaches}{126}{section.19.3}%
\contentsline {subsection}{\numberline {19.3.1}Whole genome sequencing}{126}{subsection.19.3.1}%
\contentsline {subsection}{\numberline {19.3.2}Exome sequencing}{126}{subsection.19.3.2}%
\contentsline {subsection}{\numberline {19.3.3}Transcriptome sequencing}{127}{subsection.19.3.3}%
\contentsline {section}{\numberline {19.4}Detecting classes of genome alterations}{127}{section.19.4}%
\contentsline {subsection}{\numberline {19.4.1}Somatic nucleotide substitutions and small insertion and deletion mutations}{127}{subsection.19.4.1}%
\contentsline {subsection}{\numberline {19.4.2}Copy number}{127}{subsection.19.4.2}%
\contentsline {subsection}{\numberline {19.4.3}Chromosomal rearrangements}{127}{subsection.19.4.3}%
\contentsline {subsection}{\numberline {19.4.4}Microbe-discovery methods}{128}{subsection.19.4.4}%
\contentsline {section}{\numberline {19.5}Computational issues}{128}{section.19.5}%
\contentsline {subsection}{\numberline {19.5.1}Alignment and assembly}{128}{subsection.19.5.1}%
\contentsline {subsection}{\numberline {19.5.2}mutations detection}{128}{subsection.19.5.2}%
\contentsline {subsection}{\numberline {19.5.3}Validation of mutation and rearrangement calls}{128}{subsection.19.5.3}%
\contentsline {chapter}{\numberline {20}Integrative genomics viewer}{130}{chapter.20}%
\contentsline {section}{\numberline {20.1}Introduction}{130}{section.20.1}%
\contentsline {chapter}{\numberline {21}Tumour heterogeneity and resistance to cancer therapies}{131}{chapter.21}%
\contentsline {section}{\numberline {21.1}Abstract}{131}{section.21.1}%
\contentsline {subsection}{\numberline {21.1.1}Introduction}{131}{subsection.21.1.1}%
\contentsline {section}{\numberline {21.2}Causes of intratumoral heterogeneity}{131}{section.21.2}%
\contentsline {subsection}{\numberline {21.2.1}Genomic instability}{131}{subsection.21.2.1}%
\contentsline {subsection}{\numberline {21.2.2}The clonal evolution and selection hypothesis}{132}{subsection.21.2.2}%
\contentsline {section}{\numberline {21.3}The spectrum of tumour heterogeneity}{132}{section.21.3}%
\contentsline {subsection}{\numberline {21.3.1}Spatial heterogeneity}{132}{subsection.21.3.1}%
\contentsline {subsubsection}{\numberline {21.3.1.1}Heterogeneity at a single disease site}{132}{subsubsection.21.3.1.1}%
\contentsline {subsubsection}{\numberline {21.3.1.2}Comparison of spatially distinct disease sites}{132}{subsubsection.21.3.1.2}%
\contentsline {subsection}{\numberline {21.3.2}Temporal heterogeneity}{133}{subsection.21.3.2}%
\contentsline {subsubsection}{\numberline {21.3.2.1}Genomic complexity might increase with exposure to targeted therapies}{133}{subsubsection.21.3.2.1}%
\contentsline {subsubsection}{\numberline {21.3.2.2}Longitudinal sampling provides insight into temporal heterogeneity}{133}{subsubsection.21.3.2.2}%
\contentsline {subsubsection}{\numberline {21.3.2.3}Residual drug-tolerant cells can foster temporal heterogeneity}{133}{subsubsection.21.3.2.3}%
\contentsline {section}{\numberline {21.4}Noninvasive monitoring of heterogeneity}{134}{section.21.4}%
\contentsline {subsection}{\numberline {21.4.1}Analysis of ctDNA}{134}{subsection.21.4.1}%
\contentsline {section}{\numberline {21.5}Overcoming heterogeneity}{134}{section.21.5}%
\contentsline {chapter}{\numberline {22}Unravelling the clonal hierarchy of somatic genomic aberrations}{136}{chapter.22}%
\contentsline {section}{\numberline {22.1}Introduction}{136}{section.22.1}%
\contentsline {subsection}{\numberline {22.1.1}Abstract}{136}{subsection.22.1.1}%
\contentsline {subsection}{\numberline {22.1.2}Background}{136}{subsection.22.1.2}%
\contentsline {section}{\numberline {22.2}Results}{137}{section.22.2}%
\contentsline {subsection}{\numberline {22.2.1}Clonality assessment of aberrations from sequencing reads}{137}{subsection.22.2.1}%
\contentsline {subsection}{\numberline {22.2.2}Inferring the order of mutations in a tumour sample}{138}{subsection.22.2.2}%
\contentsline {subsection}{\numberline {22.2.3}In silico and in situ experimental validation}{138}{subsection.22.2.3}%
\contentsline {subsection}{\numberline {22.2.4}Comparative analysis reveals different mechanisms of tumour deregulation}{138}{subsection.22.2.4}%
\contentsline {subsection}{\numberline {22.2.5}Clonal hierarchy of genomic aberrations}{139}{subsection.22.2.5}%
\contentsline {section}{\numberline {22.3}Materials and methods}{139}{section.22.3}%
\contentsline {subsection}{\numberline {22.3.1}CLONET pipeline}{139}{subsection.22.3.1}%
\contentsline {subsection}{\numberline {22.3.2}CLONET on exome and targeted sequencing data}{139}{subsection.22.3.2}%
\contentsline {subsection}{\numberline {22.3.3}Expected distribution of the allelic fraction of a genomic segment}{139}{subsection.22.3.3}%
\contentsline {subsection}{\numberline {22.3.4}Estimated proportion of neutral reads for a genomic segment}{140}{subsection.22.3.4}%
\contentsline {subsection}{\numberline {22.3.5}From neutral to non-aberrant reads}{140}{subsection.22.3.5}%
\contentsline {subsection}{\numberline {22.3.6}From aberrant reads to aberrant cells}{140}{subsection.22.3.6}%
\contentsline {subsection}{\numberline {22.3.7}Uncertainty assessment and its propagation to clonality estimates}{141}{subsection.22.3.7}%
\contentsline {subsection}{\numberline {22.3.8}Clonality of bi-allelic deletion}{141}{subsection.22.3.8}%
\contentsline {chapter}{\numberline {23}TPES: timor purity estimation from SNVs}{142}{chapter.23}%
\contentsline {section}{\numberline {23.1}Abstract}{142}{section.23.1}%
\contentsline {subsection}{\numberline {23.1.1}Introduction}{142}{subsection.23.1.1}%
\contentsline {section}{\numberline {23.2}Materials and methods}{142}{section.23.2}%
\contentsline {chapter}{\numberline {24}SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines}{144}{chapter.24}%
\contentsline {section}{\numberline {24.1}Abstract}{144}{section.24.1}%
\contentsline {subsection}{\numberline {24.1.1}Introduction}{144}{subsection.24.1.1}%
\contentsline {section}{\numberline {24.2}Material and methods}{144}{section.24.2}%
\contentsline {subsection}{\numberline {24.2.1}Genotype distance}{144}{subsection.24.2.1}%
\contentsline {subsection}{\numberline {24.2.2}SNP panel selection procedure}{145}{subsection.24.2.2}%
\contentsline {subsection}{\numberline {24.2.3}SPIA probabilistic test on cell line genotype distance}{145}{subsection.24.2.3}%
